Spexis AG announced a private placement of secured subordinated convertible debt for the gross proceeds of $4.5 million on April 18, 2023. The transaction included participation from returning investor Spexis AG. The company issued interest-bearing subordinated convertible debt financing converting into equity with partial warrant coverage.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.063 CHF | -0.94% | -1.25% | +53.66% |
05-01 | SIX Swiss Exchange Approves Delay in Spexis' FY23 Annual Report Publication | MT |
04-17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+53.66% | 4.7M | |
-2.42% | 88.47B | |
+2.76% | 40.71B | |
-13.92% | 32.43B | |
+50.51% | 24.28B | |
-15.25% | 15.52B | |
-39.93% | 12.17B | |
-9.08% | 12B | |
-14.80% | 12.01B | |
+6.22% | 8.87B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Spexis AG announced that it has received $4.5 million in funding from SPRIM Ventures